Axovant Sciences (AXON) Trading Down 7.5%

Shares of Axovant Sciences Ltd (NASDAQ:AXON) dropped 7.5% during trading on Thursday . The stock traded as low as $2.26 and last traded at $2.34. Approximately 1,025,319 shares were traded during mid-day trading, a decline of 62% from the average daily volume of 2,714,182 shares. The stock had previously closed at $2.53.

AXON has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Axovant Sciences in a research report on Monday, August 13th. BidaskClub raised shares of Axovant Sciences from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 1st. Zacks Investment Research raised shares of Axovant Sciences from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a research report on Tuesday, October 9th. Oppenheimer reissued a “hold” rating on shares of Axovant Sciences in a research report on Monday, July 9th. Finally, Cowen reissued a “hold” rating on shares of Axovant Sciences in a research report on Thursday, September 20th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $4.85.

The company has a current ratio of 2.34, a quick ratio of 2.34 and a debt-to-equity ratio of 1.48. The firm has a market capitalization of $285.67 million, a PE ratio of -1.05 and a beta of -0.01.

Axovant Sciences (NASDAQ:AXON) last posted its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.33). Equities analysts predict that Axovant Sciences Ltd will post -1.67 EPS for the current year.

In other news, Director George Bickerstaff acquired 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 9th. The stock was acquired at an average cost of $2.07 per share, with a total value of $51,750.00. Following the acquisition, the director now owns 50,000 shares in the company, valued at $103,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 6.00% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC boosted its holdings in shares of Axovant Sciences by 1,627.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 62,139 shares of the biotechnology company’s stock worth $141,000 after buying an additional 58,541 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Axovant Sciences by 2,519.0% during the 1st quarter. JPMorgan Chase & Co. now owns 183,223 shares of the biotechnology company’s stock worth $244,000 after buying an additional 176,227 shares during the period. GSA Capital Partners LLP bought a new stake in shares of Axovant Sciences during the 2nd quarter worth $338,000. Paloma Partners Management Co bought a new stake in shares of Axovant Sciences during the 2nd quarter worth $356,000. Finally, A.R.T. Advisors LLC boosted its holdings in shares of Axovant Sciences by 148.9% during the 1st quarter. A.R.T. Advisors LLC now owns 416,302 shares of the biotechnology company’s stock worth $553,000 after buying an additional 249,074 shares during the period. 9.38% of the stock is owned by institutional investors and hedge funds.

Axovant Sciences Company Profile (NASDAQ:AXON)

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.

Further Reading: Exchange-Traded Funds (ETFs)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply